Showing results (151-160 of 186) with videos related to
Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2019
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin LymphomaRadhakrishnan Ramchandren, Ranjana H Advani, Stephen M Ansell, et al.Blood|August 10, 2019
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease modelShyril O'Steen, Melissa L Comstock, Johnnie J Orozco, et al.Blood|November 19, 2015
Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftmentJohnnie J Orozco, Aimee Kenoyer, Ethan R Balkin, et al.Radiation Research|March 11, 2011
Blood-based detection of radiation exposure in humans based on novel phospho-Smc1 ELISARichard G Ivey, Heather D Moore, Uliana J Voytovich, et al.Blood|November 22, 2017
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignanciesDamian J Green, Shyril O'Steen, Yukang Lin, et al.Journal of Cancer Survivorship : Research and Practice|October 10, 2020
Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trialEric J Chow, David R Doody, Chongzhi Di, et al.British Journal of Haematology|February 12, 2022
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemiaChaitra Ujjani, Mazyar Shadman, Ryan C Lynch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2025
Remission Assessment by Circulating Tumor DNA in Large B-cell LymphomaMark Roschewski, David M Kurtz, Jason R Westin, et al.Cancer Research|September 4, 2016
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell CancersDamian J Green, Shani L Frayo, Yukang Lin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphomaAnas Younes, Ajay K Gopal, Scott E Smith, et al.Pageof 19